Inclusion of Patients With HIV in Anti–PD-1/PD-L1 Cancer Trials Has Increased

A recent study identified an increasing inclusion rate of individuals with HIV in clinical trials of anti–programmed cell death protein 1 and anti–programmed death ligand 1 (anti–PD-1/PD-L1) therapy for patients with cancer, in accordance with efforts of the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute. "Anti–PD-1 and anti–PD-L1 immune checkpoint blockade (ICB) constitutes the therapeutic backbone for multiple malignant neoplasms," write the authors, led by Josh...
Continue reading

Pralsetinib Approved For Patients with Advanced or Metastatic RET-Altered Medullary Thyroid Cancer

The FDA has approved pralsetinib (GAVRETOTM, Blueprint Medicines Corporation) for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) that requires systemic therapy and for patients with RET fusion-positive thyroid cancer who require systemic therapy and whose disease is refractory to radioactive iodine therapy. The approval was based on ARROW (NCT03037385), an open label, multi-cohort phase 1/2 clinical trial led by f...
Continue reading

Naxitamab Plus GM-CSF Approved For R/R High-Risk Neuroblastoma in Bone or Bone Marrow

The FDA has approved naxitamab (Danyelza®, Y-mAbs Therapeutics, Inc.) plus granulocyte-macrophage colony-stimulating factor (GM-CSF) for pediatric patients aged one year and older and for adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have experienced a partial or minor response to prior therapy, or who have stable disease. The approval was based on two open-label clinical trials, Study 201 and Study 12-230. "Neuroblastoma is a rare cancer but r...
Continue reading

African American Men With Prostate Cancer More Likely to Experience Decisional Regret

African American patients are more likely to experience regret about prostate cancer-related decisions compared with non-African American patients, according to the results of a cohort study now published in the Journal of Urology. "African American men are more likely to be diagnosed with, die of, and experience decisional regret about their prostate cancer than non-African American men," write the authors, led by Molly DeWitt-Foy, MD, a urology resident at the Cleveland Clinic. "Although ...
Continue reading

Elevated Circulating Tumor DNA Associated With Lower Disease-Free Survival in Breast Cancer

In a meta-analysis now published in JAMA Network Open, elevated plasma circulating tumor DNA (ctDNA) was linked to an increased risk of relapse in patients with metastatic and locally advanced breast cancer, suggesting that ctDNA detection may help determine response to treatment and increase the possibility of early detection of progression and recurrence. "Circulating tumor DNA is a subgroup of cell-free DNA that is present in healthy individuals and is released from nonmalignant cells, and it...
Continue reading

Copyright © 2021 Oncology Data Advisor. All rights reserved.